Published in Vaccine on December 17, 2007
Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health (2010) 1.31
Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health (2009) 1.27
Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis (2012) 1.16
A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother (2013) 0.94
Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective. Vaccine (2011) 0.82
Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysis. PLoS One (2009) 0.82
Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health (2010) 0.81
Systematic review of the economic value of diarrheal vaccines. Hum Vaccin Immunother (2014) 0.79
Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model. Libyan J Med (2014) 0.78
Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany? Health Econ Rev (2013) 0.76
Economic evidence on the health impacts of climate change in europe. Environ Health Insights (2014) 0.76
Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries. Drugs R D (2012) 0.76
Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review. Hum Vaccin Immunother (2016) 0.75
Understanding the dynamics of Ebola epidemics. Epidemiol Infect (2006) 5.81
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb. J Morphol (1994) 2.99
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut (2008) 2.60
Morphologic, cytogenetic and virologic studies in vitro of a malignant lymphoma from an African child. Int J Cancer (1966) 2.51
Inhibition of the primary in vitro antibody response by interferon preparations. J Immunol (1975) 2.35
The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.31
A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis (1975) 2.14
The effect of interferon on SV-40 T antigen production in SV-40-transformed cells. Virology (1967) 2.13
Relative ability of mitogens to stimulate production of interferon by lymphoid cells and to induce suppression of the in vitro immune response. Proc Soc Exp Biol Med (1977) 2.07
Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science (1968) 2.02
Capillary refill time exploration during septic shock. Intensive Care Med (2014) 1.99
Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science (2001) 1.93
Improved assays for a variety of interferons. 1. Proc Soc Exp Biol Med (1972) 1.79
High interferon producing line of transformed murine cells. J Gen Virol (1972) 1.79
Role of interferon during viremia. II. Protective action of circulating interferon. J Immunol (1966) 1.76
Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature-sensitive recombinant virus. J Infect Dis (1973) 1.70
Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J (2006) 1.67
Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J (2009) 1.62
Virus plaque-reduction assay for interferon: microplaque and regular macroplaque reduction assays. Methods Enzymol (1981) 1.62
Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol (1985) 1.61
The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect (2005) 1.60
Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002-2003. Epidemiol Infect (2007) 1.54
The role of interferon in the inhibition of SV40 transformation of mouse cell line 3T3. Proc Natl Acad Sci U S A (1965) 1.52
General considerations of the interferon system. Tex Rep Biol Med (1977) 1.52
IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol (2001) 1.49
European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine (2003) 1.48
The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiol Infect (2000) 1.48
Kinetics of serum interferon response in mice after single and multiple injections of polyI-poly C. Proc Soc Exp Biol Med (1971) 1.47
Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2010) 1.45
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients. Infect Dis (Lond) (2015) 1.42
Identification of a subpopulation of mouse lymphoid cells required for interferon production after stimulation with mitogens. J Immunol (1974) 1.41
Unexpectedly rapid action of human interferon in physiological conditions. Nature (1975) 1.41
Peripheral microcirculatory exploration during mechanical ventilation weaning. Minerva Anestesiol (2014) 1.38
Evaluation of an interferon inducer in viral respiratory disease. JAMA (1972) 1.37
Interleukin-1 alpha mediates the enhanced expression of intercellular adhesion molecule-1 in pulmonary epithelial cells infected with respiratory syncytial virus. Am J Respir Cell Mol Biol (1995) 1.36
Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice. Nature (1976) 1.35
Sentinel monitoring of general community health during the 1998 World Football Cup. Rev Epidemiol Sante Publique (2001) 1.34
Some factors affecting the interferon-induced antiviral state. Proc Soc Exp Biol Med (1967) 1.33
The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia (2008) 1.33
Interferon-induced transfer of viral resistance between animal cells. Nature (1977) 1.31
Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene (2010) 1.31
Effect of interferon on early interferon production. Science (1966) 1.30
Mechanism of recovery from systemic vaccinia virus infection. I. The effects of cyclophosphamide. J Exp Med (1972) 1.30
Respiratory syncytial virus infection of human respiratory epithelial cells up-regulates class I MHC expression through the induction of IFN-beta and IL-1 alpha. J Immunol (1996) 1.29
Sensitivity of common respiratory viruses to an interferon inducer in human cells. Lancet (1969) 1.29
Growth of Toxoplasma gondii in various tissue cultures treated with In-Cn or interferon. Proc Soc Exp Biol Med (1973) 1.26
Role of interferon in streptococcal infection in the mouse. Microb Pathog (1986) 1.24
Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS (2000) 1.23
Effects of interferon inducers on the intracellular growth of the protozoan parasite, Leishmania donovani. Nature (1970) 1.23
Characterization of the airborne concentrations of lead in U.S. industry. Am J Ind Med (1990) 1.23
Relationship between dose size and dose interval of polyinosinic polycytidylic acid and interferon hyporesponsiveness in mice. Proc Soc Exp Biol Med (1970) 1.22
Hmx2 homeobox gene control of murine vestibular morphogenesis. Development (2001) 1.22
Vesicular stomatitis virus plaque production in monolayer cultures with liquid overlay medium: description and adaptation to a one-day, human interferon-plaque. J Clin Microbiol (1976) 1.22
The nature of the suppressive effect of interferon and interferon inducers on the in vitro immune response. Cell Immunol (1976) 1.21
Three strains of influenza A virus (H3N2): interferon sensitivity in vitro and interferon production in volunteers. J Clin Microbiol (1976) 1.21
Antiviral action of mouse interferon in heterologous cells. J Bacteriol (1966) 1.19
Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun (1975) 1.19
Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 1.19
Blood-borne viruses in health care workers: prevention and management. J Clin Virol (2011) 1.18
Mechanism of recovery from systemic herpes simplex virus infection. I. Comparative effectiveness of antibody and reconstitution of immune spleen cells on immunosuppressed mice. J Infect Dis (1980) 1.18
Interleukin 2 enhances natural killing of normal lymphocytes. Cell Immunol (1984) 1.17
[Evaluation of tracheobronchial lesions with spiral CT: comparison between virtual endoscopy and bronchoscopy]. Radiol Med (2002) 1.17
Mengovirus-induced cytopathic effect in L-cells: protective effect of interferon. J Virol (1969) 1.16
Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study. Clin Microbiol Infect (2011) 1.16
IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol (1995) 1.16
Potentiation of antitumor effect of virus-induced interferon by mouse immune interferon preparations. J Natl Cancer Inst (1980) 1.14
Virus-induced sarcoma of mice: inhibition by a synthetic polyribonucleotide complex. Proc Natl Acad Sci U S A (1969) 1.14
Definition and classification of the interferons. Methods Enzymol (1981) 1.14
Mottling score predicts survival in septic shock. Intensive Care Med (2011) 1.14
Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Med (2006) 1.13
Effect of interferon, elevated temperature, and cell type on replication of acute hemorrhagic conjunctivitis viruses. Infect Immun (1977) 1.13
Rubella virus: role of interferon during infection of African green monkey kidney tissue cultures. J Immunol (1967) 1.12
Broadly active inhibitor of viruses spontaneously produced by many cell types in culture. Infect Immun (1981) 1.12
[Inguinal hernia repair: time interval between surgical repair and recurrence]. J Chir (Paris) (2007) 1.10
The effect of an interferon inducer on influenza virus. Bull World Health Organ (1969) 1.10
Interferon: lack of detectable uptake by cells. Science (1966) 1.09
Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis. Clin Microbiol Infect (2009) 1.08
Interferon in rabbit brain, cerebrospinal fluid and serum following administration of polyinosinic-polycytidylic acid. J Immunol (1970) 1.07
Pesticide-related illness among migrant farm workers in the United States. Int J Occup Environ Health (2002) 1.07
Induction of the interferon system by various inducers. Proc Soc Exp Biol Med (1968) 1.05
The biological significance of the interferon system. Arch Intern Med (1970) 1.05
Entamoeba histolytica causes intestinal secretion: role of serotonin. Science (1983) 1.05
Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis (2007) 1.04
Direct cytolysis by partially-purified preparations of immune interferon. Int J Cancer (1982) 1.04
Influence of vaccination coverage on pertussis transmission in France. Lancet (1999) 1.03
Comparative effectiveness of six antiviral agents in Herpes simplex type 1 infection of mice. Proc Soc Exp Biol Med (1976) 1.02
Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother (1977) 1.01
Protection against herpes virus and encephalomyocarditis virus encephalitis with a double-stranded RNA inducer of interferon. Proc Soc Exp Biol Med (1970) 1.01
Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health (2007) 1.01
Effect of crude and purified interferons on the gowth of uninfected cells in culture. Proc Soc Exp Biol Med (1966) 1.00
Preventing sexual transmission of HIV: anti-HIV bioregulatory and homeostatic components of commercial sexual lubricants. J Biol Regul Homeost Agents (2005) 1.00
Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. HIV Med (2011) 0.99
Cell-produced viral inhibitor: possible mechanism of action and chemical composition. Infect Immun (1981) 0.99
Inhibitory effect of interferon on murine sarcoma and leukaemia virus infection in vitro. Nature (1969) 0.98
Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach. Euro Surveill (2014) 0.98
Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis (2010) 0.98
Comparative production of interferon by explanted lymphoreticular tissue and alveolar macrophages from rabbits and humans. Infect Immun (1976) 0.97